Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA

Shi Cheng Zhao, Debabrata Banerjee, Shin Mineishi, Joseph R. Bertino

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

To test the concept that protection of bone marrow progenitor cells via introduction of a drug resistance gene would allow larger and curative doses of chemotherapy to be administered, we used mice bearing a transplanted breast cancer as a model system. Mice bearing the E0771 tumor were treated with lethal doses of cyclophosphamide (CPA) and rescued from toxicity by administration of bone marrow transduced with a mutant dihydrofolate reductase (DHFR) cDNA (Ser-31) in a retroviral construct. Animals receiving marrow not transduced with mutant DHFR cDNA died from methotrexate (MTX) toxicity, whereas mice transduced with mutant DHFR cDNA containing marrow were able to tolerate MTX treatment post-transplant; 44% of the mice had no demonstrable tumor when sacrificed on day 52. Another control group of mice treated with CPA and transplanted but not treated with MTX post-transplant succumbed to tumor regrowth. These data provide a strong rationale for the use of drug resistance genes to protect marrow from drug toxicity because the increase in dose tolerated may result in an improved cure rate of chemosensitive tumors.

Original languageEnglish (US)
Pages (from-to)903-909
Number of pages7
JournalHuman Gene Therapy
Volume8
Issue number8
DOIs
StatePublished - May 20 1997

Fingerprint

Tetrahydrofolate Dehydrogenase
Methotrexate
Complementary DNA
Bone Marrow
Breast Neoplasms
Transplants
Drug Resistance
Cyclophosphamide
Neoplasms
Drug-Related Side Effects and Adverse Reactions
Bone Marrow Cells
Genes
Stem Cells
Drug Therapy
Control Groups

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

@article{ffb289a128e04db780bc0adc8a3cccac,
title = "Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA",
abstract = "To test the concept that protection of bone marrow progenitor cells via introduction of a drug resistance gene would allow larger and curative doses of chemotherapy to be administered, we used mice bearing a transplanted breast cancer as a model system. Mice bearing the E0771 tumor were treated with lethal doses of cyclophosphamide (CPA) and rescued from toxicity by administration of bone marrow transduced with a mutant dihydrofolate reductase (DHFR) cDNA (Ser-31) in a retroviral construct. Animals receiving marrow not transduced with mutant DHFR cDNA died from methotrexate (MTX) toxicity, whereas mice transduced with mutant DHFR cDNA containing marrow were able to tolerate MTX treatment post-transplant; 44{\%} of the mice had no demonstrable tumor when sacrificed on day 52. Another control group of mice treated with CPA and transplanted but not treated with MTX post-transplant succumbed to tumor regrowth. These data provide a strong rationale for the use of drug resistance genes to protect marrow from drug toxicity because the increase in dose tolerated may result in an improved cure rate of chemosensitive tumors.",
author = "Zhao, {Shi Cheng} and Debabrata Banerjee and Shin Mineishi and Bertino, {Joseph R.}",
year = "1997",
month = "5",
day = "20",
doi = "10.1089/hum.1997.8.8-903",
language = "English (US)",
volume = "8",
pages = "903--909",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA. / Zhao, Shi Cheng; Banerjee, Debabrata; Mineishi, Shin; Bertino, Joseph R.

In: Human Gene Therapy, Vol. 8, No. 8, 20.05.1997, p. 903-909.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA

AU - Zhao, Shi Cheng

AU - Banerjee, Debabrata

AU - Mineishi, Shin

AU - Bertino, Joseph R.

PY - 1997/5/20

Y1 - 1997/5/20

N2 - To test the concept that protection of bone marrow progenitor cells via introduction of a drug resistance gene would allow larger and curative doses of chemotherapy to be administered, we used mice bearing a transplanted breast cancer as a model system. Mice bearing the E0771 tumor were treated with lethal doses of cyclophosphamide (CPA) and rescued from toxicity by administration of bone marrow transduced with a mutant dihydrofolate reductase (DHFR) cDNA (Ser-31) in a retroviral construct. Animals receiving marrow not transduced with mutant DHFR cDNA died from methotrexate (MTX) toxicity, whereas mice transduced with mutant DHFR cDNA containing marrow were able to tolerate MTX treatment post-transplant; 44% of the mice had no demonstrable tumor when sacrificed on day 52. Another control group of mice treated with CPA and transplanted but not treated with MTX post-transplant succumbed to tumor regrowth. These data provide a strong rationale for the use of drug resistance genes to protect marrow from drug toxicity because the increase in dose tolerated may result in an improved cure rate of chemosensitive tumors.

AB - To test the concept that protection of bone marrow progenitor cells via introduction of a drug resistance gene would allow larger and curative doses of chemotherapy to be administered, we used mice bearing a transplanted breast cancer as a model system. Mice bearing the E0771 tumor were treated with lethal doses of cyclophosphamide (CPA) and rescued from toxicity by administration of bone marrow transduced with a mutant dihydrofolate reductase (DHFR) cDNA (Ser-31) in a retroviral construct. Animals receiving marrow not transduced with mutant DHFR cDNA died from methotrexate (MTX) toxicity, whereas mice transduced with mutant DHFR cDNA containing marrow were able to tolerate MTX treatment post-transplant; 44% of the mice had no demonstrable tumor when sacrificed on day 52. Another control group of mice treated with CPA and transplanted but not treated with MTX post-transplant succumbed to tumor regrowth. These data provide a strong rationale for the use of drug resistance genes to protect marrow from drug toxicity because the increase in dose tolerated may result in an improved cure rate of chemosensitive tumors.

UR - http://www.scopus.com/inward/record.url?scp=0030999647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030999647&partnerID=8YFLogxK

U2 - 10.1089/hum.1997.8.8-903

DO - 10.1089/hum.1997.8.8-903

M3 - Article

C2 - 9195212

AN - SCOPUS:0030999647

VL - 8

SP - 903

EP - 909

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 8

ER -